Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants

Ng, P. C.; So, K. W.; Fung, K. S. C.; Lee, C. H.; Fok, T. F.; Wong, E.; Wong, W.; Cheung, K. L.; Cheng, A. F. B.
May 2001
Archives of Disease in Childhood -- Fetal & Neonatal Edition;May2001, Vol. 84 Issue 3, pF177
Academic Journal
Aim--To evaluate the effectiveness of oral erythromycin as a prokinetic agent for the treatment of moderately severe gastrointestinal dysmotility in preterm very low birthweight infants. Methods--A prospective, double blind, randomised, placebo controlled study in a tertiary referral centre of a university teaching hospital was conducted on 56 preterm infants (< 1500 g) consecutively admitted to the neonatal unit. The infants were randomly allocated by minimisation to receive oral erythromycin (12.5 mg/kg, every six hours for 14 days) or an equivalent volume of placebo solution (normal saline) if they received less than half the total daily fluid intake or less than 75 ml/kg/day of milk feeds by the enteral route on day 14 of life. The times taken to establish half, three quarters, and full enteral feeding after the drug treatment were compared between the two groups. Potential adverse effects of oral erythromycin and complications associated with parenteral nutrition were assessed as secondary outcomes. Results--Twenty seven and 29 infants received oral erythromycin and placebo solution respectively. The times taken to establish half, three quarters, and full enteral feeding after the drug treatment were significantly shorter in the group receiving oral erythromycin than in those receiving the placebo (p < 0.05, p < 0.05 and p < 0.0001 respectively). There was also a trend suggesting that more infants with prolonged feed intolerance developed cholestatic jaundice in the placebo than in the oral erythromycin group (10 v 5 Infants). None of the infants receiving oral erythromycin developed cardiac dysrhythmia, pyloric stenosis, or septicaemia caused by multiresistant organisms. Conclusions--Oral erythromycin is effective in facilitating enteral feeding in preterm very low birthweight infants with moderately severe gastrointestinal dysmotility. Treated infants can achieve full enteral feeding 10 days earlier, and this may result in a substantial saving on hyperalimentation. However, until the safety of erythromycin has been confirmed in preterm infants, this treatment modality should remain experimental. Prophylactic or routine use of this medication for treatment of mild cases of gastrointestinal dysmotility is probably not warranted at this stage.


Related Articles

  • Oral Erythromycin Accelerates Impaired Gastrointestinal Motility After Endoscopic Mucosal Resection. Motoyasu Kusano; Yasuyuki Shimoyama; Tsutomu Horikoshi; Toshikazu Sekiguchi; Masatomo Mori // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2211 

    Abstract  Gastrointestinal motility may be impaired after endoscopic mucosal resection of gastric lesions. We investigated whether oral erythromycin could improve motility. Twenty patients were divided randomly into groups that received oral omeprazole with or without...

  • Motilin, Motility, and Erythromycin--Finally Some Mechanisms. Roy, H. K.; Thompson, Jon S. // American Journal of Gastroenterology;Nov1999, Vol. 94 Issue 11, p3108 

    Discusses research being done on the molecular regulation of gastrointestinal motility. Reference to a study by S. D. Feighner and colleagues, published in a 1999 issue of the "Science"; Mechanism of erythromycin's potent prokinetic effect; Amino acid sequence of the orphan receptor GPR 38.

  • Erythromycin: A Motilin Agonist and Gastrointestinal Prokinetic Agent. Weber Jr., Frederick H.; Richards, Robert D.; McCallum, Richard W. // American Journal of Gastroenterology;Apr1993, Vol. 88 Issue 4, p485 

    Erythromycin, a commonly used antibiotic, has recently emerged as a potential gastrointestinal prokinetic agent. This follows a decade of research into the mechanism of well-recognized gastrointestinal side effects of erythromycin. Early investigations demonstrated that erythromycin increased...

  • The Effects of Eupatilin (Stillen) on Motility of Human Lower Gastrointestinal Tracts. Seung-Bum Ryoo; Heung-Kwon Oh; Yu, Sung A.; Sang Hui Moon; Eun Kyung Choe; Tae Young Oh; Kyu Joo Park // Korean Journal of Physiology & Pharmacology;Oct2014, Vol. 18 Issue 5, p383 

    Gastrointestinal motility consists of phasic slow-wave contractions and the migrating motor complex (MMC). Eupatilin (Stillen®) has been widely used to treat gastritis and peptic ulcers, and various cytokines and neuropeptides are thought to be involved, which can affect gastrointestinal...

  • Erythromycin Eye Ointment: Effect on Gastrointestinal Motility. Moussa, Fathy; Alaswad, Bashar; Garcia, Jose // American Journal of Gastroenterology;Mar2000, Vol. 95 Issue 3, p826 

    Assesses the effect of erythromycin ointment (EM) on gastrointestinal motility. Comparison between the time of first meconium expulsion in newborns receiving ophthalmic silver nitrate and ophthalmic EM; Information on erythromycin.

  • Erythromycin Accelerates Gastric Emptying of Indigestible Solids and Transpyloric Migration of the Tip of an Enteral Feeding Tube in Fasting and Fed States. Keshavarzian, Ali; Isaac, Ronald M. // American Journal of Gastroenterology;Feb1993, Vol. 88 Issue 2, p193 

    Erythromycin has been shown to initiate gastric interdigestive migrating motor complexes, which are the motor events responsible for gastric emptying of indigestible solids. Hence, erythromycin should also accelerate gastric emptying of indigestible particles and facilitate transpyloric...

  • Erythromycin.  // Reactions Weekly;11/8/2008, Issue 1227, p12 

    The article describes a case of hypertrophic pyloric stenosis in mono-ovular extremely preterm twins following treatment with erythromycin for gastrointestinal dysmotility and promotion of enteral feeding. The 15-week-old premature male neonates developed feeding intolerance, loose stools,...

  • Perforation of the colon after administration of neostigmine. Mollema, R.; Spijkstra, J. Jaap; Polderman, K. H.; Gelissen, H. P. M. M.; Girbes, A. R. J. // Intensive Care Medicine;Apr2004, Vol. 30 Issue 4, p730 

    Looks into a study on gastrointestinal motility. Type of treatment used for patients with this condition; Initiation of neostigmine infusion to promote bowel movement; Confirmation of the existence of a perforated diverticulitis of the sigmoid through a pathological examination.

  • Simulation and analysis of spatio-temporal maps of gastrointestinal motility. Lammers, Wim J. E. P.; Cheng, Leo K. // BioMedical Engineering OnLine;2008, Vol. 7, Special section p1 

    Background: Spatio-temporal (ST) maps provide a method for visualizing a temporally evolving and spatially varying field, which can also be used in the analysis of gastrointestinal motility. However, it is not always clear what the underlying contractions are that are represented in ST maps and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics